ANTX Stock — AN2 Therapeutics Inc.: Cash, EV, Pipeline

Share price

$5.05

Market cap

$190.6M

Cash

$78.4M

Enterprise value

$112.2M

Balance sheet

Cash	$78.4M
Debt	$0.0M
Net cash	$78.4M
Enterprise value	$112.2M
Basic shares	36.3M shares
Fully diluted shares	45.6M shares
Fully diluted market cap	$230.3M
Cash per share	$2.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ANTX daily closes…

Loading price history…

Pipeline assets

Epetraborole

Phase 2 · Active Modality: oral boron-based small molecule

Target LeuRS (leucyl-tRNA synthetase)

Partnerships Anacor Pharmaceuticals: exclusive worldwide license (boron chemistry compounds); Brii Biosciences: licensed-product rights in China, Hong Kong, Taiwan and Macau; NIAID: cost-reimbursement contract (up to $9.3M cumulative committed) supporting late-stage development

Indications

Polycythemia vera (phlebotomy-dependent) (Phase 2)
M. abscessus complex lung disease (Phase 2)
Acute systemic melioidosis and other biothreat pathogens (Preclinical)

Catalysts

— Q3 2026
— Q4 2026

Status note PV Phase 2 = sentinel + dose-optimization + randomized placebo-controlled parts, 40-50 pts, India. M. abscessus Phase 2 = investigator-initiated study with OHSU (IND cleared Dec 2025). Melioidosis Phase 2 proof-of-concept trial pending federal funding; NIAID contract options reduced $9.0M in June 2025 under a 2025 Executive Order cost-efficiency initiative.

AN2-502998

Phase 1 · Active Modality: oral boron-based small molecule

Target CPSF3

Indications

Chagas disease (Phase 1)

Catalysts

— 2026

Status note Phase 1 first-in-human trial in healthy volunteers commenced August 2025; initial clinical data were expected Q1 2026 per the filing.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	58,808	+44,947	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ANTX — AN2 Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders